newsfilter
← Latest News
GlobeNewswire·

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc.